Kodiak Sciences
Price & Volume
Stats
See moreOpen | $5.44 |
Previous Close | $5.50 |
Day Range | $5.39-$5.51 |
52W Range | $2.08-$7.77 |
Market Cap | $289.3M |
Shares Short | 1M |
Financials
See moreRevenue (12 Mos) | $0 |
Revenue Growth (YoY) | 0% |
Gross Profit (12 Mos) | $0 |
Diluted EPS | -$3.77 |
News
See moreYahoo Finance • last year
We Think Kodiak Sciences (NASDAQ:KOD) Needs To Drive Business Growth Carefully
Yahoo Finance • last year
Kodiak Sciences to Present at the Morgan Stanley 21st Annual Global Healthcare Conference
Yahoo Finance • 2 years ago
Kodiak Sciences Completes Enrollment in GLOW Phase 3 Clinical Trial of Tarcocimab Tedromer (KSI-301) in Patients with Non-Proliferative Diabetic Retinopathy
Yahoo Finance • 3 years ago
Stock rebound uncertain for U.S. biotechs as risks multiply for investors
About
CEO | Dr. Victor Perlroth M.D. |
CFO | Mr. John A. Borgeson CPA, M.B.A. |
Address | 1200 Page Mill Road, Palo Alto, CA, United States, 94304 |
Sector | Healthcare |
Industry | Biotechnology |
Full-Time Employees | 111 |
